Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.68 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16408369 | 0.93 | SCN8A (0.68) | SCN8ASCN10A | |
| SCHEMBL16408278 | 0.89 | — | — | |
| SCHEMBL16398560 | 0.88 | — | — | |
| SCHEMBL29918965 | 0.88 | — | — | |
| SCHEMBL17791069 | 0.87 | — | — | |
| SCHEMBL19547947 | 0.86 | — | — | |
| SCHEMBL16408272 | 0.86 | — | — | |
| SCHEMBL20644108 | 0.85 | SCN8A (0.70) | SCN8ASCN10A | |
| SCHEMBL16398916 | 0.85 | — | — | |
| SCHEMBL16408303 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11203571-B2 | Sulfonamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-21 | — | — | US | claimed |
| EP-3022175-B1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2017-11-08 | — | — | EP | claimed |
| US-11203571-B2 | Sulfonamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3022175-B1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3022175-B1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20160152561-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2016-06-02 | — | — | US | disclosed |
| US-20160152561-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2016-06-02 | — | — | US | disclosed |
| WO-2015010065-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11203571-B2 | Sulfonamides as modulators of sodium channels | TRPV1, SCN1A, SCN5A | SCN8A 24/4885SCN10A 7/4885 |
| US-20160152561-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN1A, SCN5A | SCN8A 24/4885SCN10A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.